-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 D7A3BrLr5lkmChCQgRSNQQ0k9rsd/Ca1ZRIG5m5g4lnYDO98j/dlTbRO7a2z2z/v
 HBRrlCfG/TzezUQMtKtEkA==

<SEC-DOCUMENT>0001297077-07-000009.txt : 20070216
<SEC-HEADER>0001297077-07-000009.hdr.sgml : 20070216
<ACCEPTANCE-DATETIME>20070216114706
ACCESSION NUMBER:		0001297077-07-000009
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20070214
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070216
DATE AS OF CHANGE:		20070216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS SPORTS INC
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-EATING & DRINKING PLACES [5810]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		07630025

	BUSINESS ADDRESS:	
		STREET 1:		2500 WILSON BLVD
		STREET 2:		SUITE 305
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201
		BUSINESS PHONE:		703-526-04

	MAIL ADDRESS:	
		STREET 1:		1749 OLD MEADOW RD
		STREET 2:		STE 610
		CITY:			MCLEAN
		STATE:			VA
		ZIP:			22102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>champions_8k-02142007.htm
<TEXT>
<html>
<head><meta content="text/html; charset=iso-8859-1">
<title>UNITED STATES</title>
</head>

<body >
<ul>
</ul>

<p>
<p align="center">
<b>UNITED STATES</b><br><b>SECURITIES AND EXCHANGE
COMMISSION</b><br><b>Washington, D.C. 20549</b><p align="center">
<b>FORM 8-K</b><p align="center">
<b>CURRENT REPORT</b><br><b>Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934</b><p align="center">
<font size="2">Date of Report (Date of earliest event reported): February 14,
2007</font><p align="center">
<b>CHAMPIONS BIOTECHNOLOGY,
INC</b><font size="2">.</font><br><font size="2">(Exact name of registrant as
specified in its charter)</font></p align="center">
<div align="center" style="position:relative; left: 0"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="203.999949" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Delaware</font></p align="center">
</td>
<td width="191.999952" colspan="1" rowspan="1" >
<p align="center">
<font size="2">0-17263</font></p align="center">
</td>
<td width="167.999958" colspan="1" rowspan="1" >
<p align="center">
<font size="2">52-1401755</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="203.999949" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(State of other jurisdiction</font></p align="center">
</td>
<td width="191.999952" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Commission</font></p align="center">
</td>
<td width="167.999958" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(IRS Employer</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="203.999949" colspan="1" rowspan="1" >
<p align="center">
<font size="2">of incorporation)</font></p align="center">
</td>
<td width="191.999952" colspan="1" rowspan="1" >
<p align="center">
<font size="2">File Number)</font></p align="center">
</td>
<td width="167.999958" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Identification No.)</font></p align="center">
</td>
</tr>
</table></div>
<p>
<p align="center">
<font size="2">2200 Wilson Blvd.</font><br><font size="2">Suite
102-316</font><br><font size="2">Arlington,
VA&nbsp;&nbsp;22201</font><br><font size="2">(Address of principal executive
offices)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Zip Code)</font><p align="center">
<font size="2">Registrant&#8217;s telephone number, including area code: (703)
526-0400</font><p align="center">
<font size="2">(Former name or former address, if changed since last
report.)</font><p>
<font size="2">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</font><p>
<font size="2">[&nbsp;&nbsp;] Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)</font><br><font size="2">[&nbsp;&nbsp;]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)</font><br><font size="2">[&nbsp;&nbsp;] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</font><br><font size="2">[&nbsp;&nbsp;] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</font></p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b></b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
<p>
<!--<a name="_Toc147111976"></a>--><font size="2"><b>Item 1.01. Entry into a Material
Definitive Agreement</b></font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February 14, 2007,
the Registrant agreed to acquire all of the patent rights underlying pending
U.S. Patent Application no. 11/673,519 and corresponding international patent
application (PCT/US2006/014449) filed under the Patent Cooperation Treaty (PCT),
both entitled &#8220;Design and Synthesis of Novel Tubulin Polymerization
Inhibitors:  Benzoylphenylurea (BPU) Sulfur Analogs.&#8221; The acquisition
represents the commencement of the Registrant&#8217;s strategy to develop a
biotechnology business based on therapeutic drug candidates among other possible
ventures.</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purchase price for
the patent rights consisted of an aggregate of up to 550,000 restricted shares
of common stock, of which 300,000 restricted shares were issued upon execution
of the acquisition agreement and 250,000 restricted shares are issuable upon the
issuance of one or patents based on U.S. Patent Application no. 11/673,519. The
Registrant has 27,624,658 issued and outstanding common shares and of those,
19,573,000 are restricted common shares.</font><p>
<font size="2">The preceding summary is qualified in its entirety by reference
to the assignment agreement, which is filed as Exhibit 10.1 to this Current
Report on Form 8-K.</font><p>
<font size="2"><b>Item 3.02. Unregistered Sales of Equity
Securities</b></font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February 14, 2007,
the Registrant issued an aggregate of 300,000 restricted shares of common stock
to four individuals in connection with the acquisition of certain patent rights
from those individuals. For a description of the material terms of the agreement
in connection with this transaction, reference is made to the disclosure made
under Item 1.01 of this Current Report on Form 8-K, which is incorporated herein
by reference. All of the individuals who received shares were accredited
investors. These shares were issued in reliance upon the exemption from
registration provided by Section 4(2) of the Securities Act based upon, among
other things, the size and manner of the offering.</font><p>
<font size="2"><b>Item 8.01. Other Events</b></font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February 14, 2007,
the Registrant issued a press release, a copy of which is attached to this
Current Report on Form 8-K as Exhibit 99.1, in connection with the transaction
described in the disclosure made under Item 1.01 of this Current Report on Form
8-K. </font><p>
<!--<a name="OLE_LINK1"></a>--><!--<a name="_Toc147111982"></a>--><font size="2"><b>Item 9.01.
Financial Statements and Exhibits</b></font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Exhibits</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Agreement,
dated February 14, 2007</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press
release, dated February 14, 2007</font></p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>-1-</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
<p align="center">
<font size="2"><b>SIGNATURES</b></font><p>
<font size="2">Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</font></p>
<div style="position:relative; left: 0"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="323.999919" colspan="2" rowspan="1" >
<p>
<font size="2">Date: February 15, 2007</font></p>
</td>
<td width="107.999973" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="202.666616" colspan="2" rowspan="1" >
<p>
<font size="2">CHAMPIONS SPORTS, INC.</font></p>
</td>
<td width="1.333333" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="6" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="6" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="6" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="167.999958" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="155.999961" colspan="1" rowspan="1" >
<p>
<font size="2"> </font></p>
</td>
<td width="107.999973" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="35.999991" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;By:</font></p>
</td>
<td width="166.666625" colspan="1" rowspan="1" >
<p style="border-bottom:solid windowtext .5pt">
<font size="2">/s/&nbsp;James Martell</font></p>
</td>
<td width="1.333333" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="167.999958" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="155.999961" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="107.999973" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="35.999991" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="166.666625" colspan="1" rowspan="1" >
<p>
<font size="2">James Martell</font></p>
</td>
<td width="1.333333" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="167.999958" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="155.999961" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="107.999973" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="35.999991" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="166.666625" colspan="1" rowspan="1" >
<p>
<font size="2">Chief Executive Officer</font></p>
</td>
<td width="1.333333" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="6" rowspan="1" >
&nbsp;</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>-2-</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
</p>


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>champions8kex10_1-agreement.htm
<DESCRIPTION>AGREEMENT
<TEXT>
<html>
<head><meta content="text/html; charset=iso-8859-1">
<title>AGREEMENT</title>
</head>

<body >
<ul>
</ul>

<p>
<font size="2">Exhibit 10.1</font><p align="center">
<font size="2"><u>AGREEMENT</u></font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS AGREEMENT,
executed in quintuplicate, is by and among Saeed R. Khan, residing in Owings
Mills, Maryland (hereinafter &#8220;Khan&#8221;), Gurulingappa Hallur, residing
in Owings Mills, Maryland (hereinafter &#8220;Hallur&#8221;), Manuel Hidalgo,
residing in Baltimore, Maryland (hereinafter &#8220;Hidalgo&#8221;), Antonio
Jimeno, residing in Baltimore, Maryland (hereinafter &#8220;Jimeno&#8221;) and
Champions Biotechnology, Inc., a Delaware corporation, located at 2200 Wilson
Boulevard, Suite 102-316, Arlington, Virginia 22201 (hereinafter
&#8220;Champions&#8221;);</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Khan, Hallur,
Hidalgo and Jimeno represent and warrant that they are the owners of the entire
and unencumbered right, title and interest in and to the following patent
applications: U.S. application no. 60/672,469, filed April 18, 2005; U.S.
application no. 60/696,672, filed July 5, 2005; U.S. application no. 60/720,755,
filed September 27, 2005; U.S. application no. 11/673,519, filed February 9,
2007; and PCT application no. PCT/US2006/014449, filed April 18, 2006
(hereinafter &#8220;the Applications&#8221;);</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Khan, Hallur,
Hidalgo and Jimeno represent and warrant that they are the inventors of the
inventions disclosed in the Applications and that no one else is an
inventor;</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Khan, Hallur,
Hidalgo and Jimeno desire to assign to Champions the entire right, title and
interest in and to the Applications, all inventions described therein, any other
applications on such invention(s) in the U.S. and in foreign countries, and all
patents issuing from the Applications, and Champions desires to acquire same;
and</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Khan, Hallur, Hidalgo
and Jimeno and Champions represent and warrant that they have not entered into
any agreements inconsistent with this Agreement;</font></p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b></b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
<p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in
consideration of the mutual promises hereinafter set forth, the parties agree as
follows:</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Khan,
Hallur, Hidalgo and Jimeno assign, convey and set over unto Champions, its
successors and assigns, the entire right, title and interest in and to the
Applications and all inventions described therein in the U.S. and in foreign
countries.</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Khan,
Hallur, Hidalgo and Jimeno shall execute all such papers as may be necessary or
proper for the filing and prosecution of such applications for patent, both
United States and foreign, as Champions may desire with respect to the
invention(s) disclosed in the Applications, and all such papers as may be
necessary for assigning to Champions their interest in and to the Applications,
corresponding applications in the U.S. and foreign countries and patents issuing
therefrom.  All actions required of Khan, Hallur, Hidalgo and Jimeno in this
paragraph shall be at no cost to them.</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly
after the Agreement is entered into, Khan, Hallur, Hidalgo and Jimeno shall
receive restricted common shares in Champions as follows: Khan 112,500 shares;
Hallur 62,500 shares; Hidalgo 62,500 shares; Jimeno 62,500 shares.</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
and if a patent issues from U.S. application no. 11/673,519, or a continuation
thereof, Khan, Hallur, Hidalgo and Jimeno shall receive additional restricted
common shares in Champions as follows:  Khan 62,500 shares; Hallur 62,500
shares; Hidalgo 62,500 shares; Jimeno 62,500 shares.</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
cost of obtaining and maintaining patent applications and patents under this
Agreement shall be borne by Champions.</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement is binding upon and shall inure to the benefit of the successors and
assigns of Champions, and to the heirs, legal representatives and successors of
Khan, Hallur, Hidalgo and Jimeno.</font></p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>2</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
<p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should
any portion or provision of this agreement be declared invalid or unenforceable
in any jurisdiction, then such portion or provision shall be deemed to be
severable from this Agreement as to such jurisdiction (but to the extent
permitted by law not elsewhere) and shall not affect the remainder
hereof.</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement may be amended, altered, or modified only in writing, specifying such
amendment, alternation or modification, executed by both parties.</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement constitutes the entire Agreement between the parties hereof with
respect to the subject matter of this Agreement, and supersedes all prior or
contemporaneous negotiations, understandings or agreements of the parties,
whether written or oral with respect to such subject matter.</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the
parties have executed this Agreement on the dates appearing below. </font></p>
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="55.999986" colspan="1" rowspan="1" >
<p>
<font size="2">Dated:</font></p>
</td>
<td width="153.333295" colspan="1" rowspan="1" >
<p style="border-bottom:solid windowtext .5pt">
<font size="2">February 14, 2007</font></p>
</td>
<td width="19.999995" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="325.333252" colspan="1" rowspan="1" >
<p style="border-bottom:solid windowtext .5pt">
<font size="2">/S/ Saeed R. Khan</font></p>
</td>
</tr>
<tr valign="top">
<td width="55.999986" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="153.333295" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="19.999995" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="325.333252" colspan="1" rowspan="1" >
<p>
<font size="2">Saeed R. Khan</font></p>
</td>
</tr>
</table></div>
<p>
</p>
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="55.999986" colspan="1" rowspan="1" >
<p>
<font size="2">Dated:</font></p>
</td>
<td width="153.333295" colspan="1" rowspan="1" >
<p style="border-bottom:solid windowtext .5pt">
<font size="2">February 14, 2007</font></p>
</td>
<td width="19.999995" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="325.333252" colspan="1" rowspan="1" >
<p style="border-bottom:solid windowtext .5pt">
<font size="2">/S/ Gurulingappa Hallur</font></p>
</td>
</tr>
<tr valign="top">
<td width="55.999986" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="153.333295" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="19.999995" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="325.333252" colspan="1" rowspan="1" >
<p>
<font size="2">Gurulingappa Hallur</font></p>
</td>
</tr>
</table></div>
<p>
</p>
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="55.999986" colspan="1" rowspan="1" >
<p>
<font size="2">Dated:</font></p>
</td>
<td width="153.333295" colspan="1" rowspan="1" >
<p style="border-bottom:solid windowtext .5pt">
<font size="2">February 14, 2007</font></p>
</td>
<td width="19.999995" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="325.333252" colspan="1" rowspan="1" >
<p style="border-bottom:solid windowtext .5pt">
<font size="2">/S/ Manuel Hidalgo</font></p>
</td>
</tr>
<tr valign="top">
<td width="55.999986" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="153.333295" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="19.999995" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="325.333252" colspan="1" rowspan="1" >
<p>
<font size="2">Manuel Hidalgo</font></p>
</td>
</tr>
</table></div>
<p>
</p>
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="55.999986" colspan="1" rowspan="1" >
<p>
<font size="2">Dated:</font></p>
</td>
<td width="153.333295" colspan="1" rowspan="1" >
<p style="border-bottom:solid windowtext .5pt">
<font size="2">February 14, 2007</font></p>
</td>
<td width="19.999995" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="325.333252" colspan="1" rowspan="1" >
<p style="border-bottom:solid windowtext .5pt">
<font size="2">/S/ Antonio Jimeno</font></p>
</td>
</tr>
<tr valign="top">
<td width="55.999986" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="153.333295" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="19.999995" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="325.333252" colspan="1" rowspan="1" >
<p>
<font size="2">Antonio Jimeno</font></p>
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>3</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
</p>
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="55.999986" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="153.333295" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="19.999995" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="325.333252" colspan="1" rowspan="1" >
<p>
<font size="2">Champions Biotechnology, Inc.</font></p>
</td>
</tr>
<tr valign="top">
<td width="55.999986" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="153.333295" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="19.999995" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="325.333252" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="55.999986" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="153.333295" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="19.999995" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="325.333252" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="55.999986" colspan="1" rowspan="1" >
<p>
<font size="2">Dated:</font></p>
</td>
<td width="153.333295" colspan="1" rowspan="1" >
<p style="border-bottom:solid windowtext .5pt">
<font size="2">February 14, 2007</font></p>
</td>
<td width="19.999995" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="325.333252" colspan="1" rowspan="1" >
<p style="border-bottom:solid windowtext .5pt">
<font size="2">/S/James Martell</font></p>
</td>
</tr>
<tr valign="top">
<td width="55.999986" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="153.333295" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="19.999995" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="325.333252" colspan="1" rowspan="1" >
<p>
<font size="2">James Martell</font></p>
</td>
</tr>
<tr valign="top">
<td width="55.999986" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="153.333295" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="19.999995" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="325.333252" colspan="1" rowspan="1" >
<p>
<font size="2">CEO and President</font></p>
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>4</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
</p>


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>champions8kex99_1-pressrel.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head><meta content="text/html; charset=iso-8859-1">
<title>Champions Sports, Inc</title>
</head>

<body >
<ul>
</ul>

<p align="center">
<p align="center">
<font color="#ff0000">CHAMPIONS  Biotechnology, Inc.</font><br>2200 Wilson
Boulevard, Suite 102-316<br>Arlington, VA 22201, USA<br>Tel:
703-526-0400<br>Fax: 703-832-8311<p align="center">
<b>Champions Biotechnology, Inc. acquires rights to cancer drug
candidates</b><p>
Arlington, VA., February 14, 2007. Champions Biotechnology, Inc. (OTC Bulletin
Board: CSBR), a development stage biotechnology company, announced today
the&nbsp;acquisition of&nbsp;patent rights&nbsp;encompassing&nbsp;two
Benzoylphenylurea (BPU)  sulfur analog compounds that have shown promising
potent activity against prostate and pancreatic cancer cell lines (<i>Journal of
Medicinal Chemistry</i>, 2006, Vol. 49, No.7, 2357-2360).&nbsp; The acquired
rights include&nbsp;pending U.S. Patent Application no. 11/673,519 and
corresponding international&nbsp;patent application (PCT/US2006/014449) filed
under the Patent Cooperation Treaty (PCT), both entitled Design and Synthesis of
Novel Tubulin Polymerization Inhibitors:&nbsp; Benzoylphenylurea (BPU) Sulfur
Analogs. <p>
These antimitotic inhibitors target MAPT (Microtubule-Associated Protein Tau)
deficient tumors, a common feature of solid tumors, and have performed better
than Docetaxel (Taxotere) in the difficult to treat direct patient xenograft
models of pancreatic cancer (<i>Journal of the National Cancer Institute</i>,
Vol. 99, Issue 2, January 17 2007, 105-107).  The Company, in exchange for
550,000 restricted shares of its common stock, was assigned all the rights in
the U.S. and in foreign countries to the applications for these inhibitors
developed at Johns Hopkins University by their inventors Drs. Saeed Khan,
Gurulingappa Hallur, Manuel Hidalgo and Antonio Jimeno. <p>
This acquisition is the Company&#8217;s initial step in building a biotechnology
company from the ground up with a future portfolio of possible therapeutic drug
candidates among other ventures that it is actively exploring. The Company plans
to develop candidates from its portfolio of therapeutic compounds and partner
with pharmaceutical and/or biotechnology partners for development, regulatory
approval and marketing as appropriate. <p>
This press release contains "forward-looking statements" (within the meaning of
the Private Securities Litigation Act of 1995) that inherently involve risk and
uncertainties. The Company generally uses words such as "believe," "may,"
"could," "will," "intend," "expect," "anticipate," "plan," and similar
expressions to identify forward-looking statements. One should not place undue
reliance on these forward-looking statements. The Company&#8217;s actual results
could differ materially from those anticipated in the forward-looking statements
for many unforeseen factors, which may include, but are not limited to, changes
in general economic conditions, the ongoing threat of terrorism, ability to have
access to financing sources on reasonable terms and other risks that are
described in this document. Although the Company believes the expectations
reflected in the forward-looking statements are reasonable, they relate only to
events as of the date on which the statements are made, and the Company&#8217;s
future results, levels of activity, performance or achievements may not meet
these expectations. The Company does not intend to update any of the
forward-looking statements after the date of this press release to conform these
statements to actual results or to changes in the Company&#8217;s expectations,
except as required by law. <p>
Contact: James Martell (703) - 526-0400</p>


</body>

</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
